Obermatt
See Similar Stocks →

Arcellx

NSQ:ACLX · US03940C1009
BiotechnologySmall

360° View

67
Price/Sales23
Price/Earnings93
Price/Book5
Dividend Yield1
Revenue Growth100
Profit Growth8
Capital Growth86
TSR 52w50
Leverage53
Liquidity37
Refinancing55
Combined64
Analyst Opinions1
Pro Holdings9
Opinion Changes42
Market Pulse82

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePrivate Company
ExchangeNASDAQGS
Founded2014
Employees216
Websitearcellx.com
ISINUS03940C1009
Last UpdateApr 2, 2026
Index & Theme
Stem Cell TherapyOncologyHematologyImmunologyBiopharmaBiotechnologyHealth CareLife SciencePharmaceutical

Description

Arcellx, Inc. (Arcellx) operates as a clinical-stage biotechnology company. The company focuses on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases. The company's novel synthetic binding sca…

Analysis

Arcellx's 360° View rank of 67 places it above its peer average — better than 67% of its true peers.

It's growing solidly (52) and on the expensive side (48). On safety it is financially sound (52), and the market shows muted sentiment (47). Taken together, its Combined rank of 64 reads as above its peer average.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
23
—
—
—
Price/Earnings
93
—
—
—
Price/Book
5
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
48
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Arcellx with its peers
Geron
NSQ:GERN
22
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sana Biotechnology
NSQ:SANA
63
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Legend Biotech
NSQ:LEGN
30
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Cartesian Therapeutics
NMQ:RNAC
20
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immunic
NAQ:IMUX
38
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kyverna Therapeutics
NSQ:KYTX
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →